These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 10027846)

  • 1. Ergoline derivative LEK-8829-induced turning behavior in rats with unilateral striatal ibotenic acid lesions: interaction with bromocriptine.
    Sprah L; Zivin M; Sket D
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1093-100. PubMed ID: 10027846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of neuroleptic activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 intrinsic activity in hemi-parkinsonian rats.
    Glavan G; Sket D; Zivin M
    Mol Pharmacol; 2002 Feb; 61(2):360-8. PubMed ID: 11809861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The D1 receptor-mediated effects of the ergoline derivative LEK-8829 in rats with unilateral 6-hydroxydopamine lesions.
    Zivin M; Sprah L; Sket D
    Br J Pharmacol; 1996 Nov; 119(6):1187-96. PubMed ID: 8937722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiparkinsonian potential of interaction of LEK-8829 with bromocriptine.
    Zivin M; Sprah L; Sket D
    Eur J Pharmacol; 1998 May; 349(2-3):151-7. PubMed ID: 9671092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841.
    Krisch I; Bole-Vunduk B; Pepelnak M; Lavric B; Ocvirk A; Budihna MV; Sket D
    J Pharmacol Exp Ther; 1994 Oct; 271(1):343-52. PubMed ID: 7965734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression.
    Morelli M; Fenu S; Pinna A; Di Chiara G
    J Pharmacol Exp Ther; 1992 Jan; 260(1):402-8. PubMed ID: 1346165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
    Wirtshafter D; Osborn CV
    Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The full D1 dopamine receptor agonist SKF-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: regulation of D1/D2 interactions by muscarinic receptors.
    Wang JQ; McGinty JF
    J Pharmacol Exp Ther; 1997 May; 281(2):972-82. PubMed ID: 9152408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions.
    Matsubara K; Shimizu K; Suno M; Ogawa K; Awaya T; Yamada T; Noda T; Satomi M; Ohtaki K; Chiba K; Tasaki Y; Shiono H
    Brain Res; 2006 Sep; 1112(1):126-33. PubMed ID: 16884702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
    McPherson RJ; Marshall JF
    Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific involvement of striatal D1 and D2 dopamine receptors in the neuroleptic catalepsy in rats.
    Wardas J; Pietraszek M; Ossowska K; Wolfarth S
    Pol J Pharmacol; 1995; 47(4):349-53. PubMed ID: 8616516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fetal ventral mesencephalic grafts functionally reduce the dopamine D2 receptor supersensitivity in partially dopamine reinnervated host striatum.
    Strömberg I; Kehr J; Andbjer B; Fuxe K
    Exp Neurol; 2000 Jul; 164(1):154-65. PubMed ID: 10877926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D1 dopamine agonist effects assessed in vivo with [14C]-2-deoxyglucose autoradiography.
    Trugman JM; Arnold WS; Touchet N; Wooten GF
    J Pharmacol Exp Ther; 1989 Sep; 250(3):1156-60. PubMed ID: 2674418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions.
    Broening HW; Morford LL; Vorhees CV
    Synapse; 2005 May; 56(2):84-93. PubMed ID: 15714503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32.
    Flores-Hernández J; Cepeda C; Hernández-Echeagaray E; Calvert CR; Jokel ES; Fienberg AA; Greengard P; Levine MS
    J Neurophysiol; 2002 Dec; 88(6):3010-20. PubMed ID: 12466426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dopamine D1 receptor agonist and D2 receptor antagonist LEK-8829 attenuates reinstatement of cocaine-seeking in rats.
    Milivojevic N; Krisch I; Sket D; Zivin M
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jun; 369(6):576-82. PubMed ID: 15138661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does adenosine receptor blockade mediate caffeine-induced rotational behavior?
    Garrett BE; Holtzman SG
    J Pharmacol Exp Ther; 1995 Jul; 274(1):207-14. PubMed ID: 7616401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuation of the locomotor-sensitizing effects of the D2 dopamine agonist bromocriptine by either the D1 antagonist SCH 23390 or the D2 antagonist raclopride.
    Wise RA; Carlezon WA
    Synapse; 1994 Jul; 17(3):155-9. PubMed ID: 7974197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of D1 and D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics.
    Meller E; Bohmaker K; Goldstein M; Friedhoff AJ
    J Pharmacol Exp Ther; 1985 Jun; 233(3):656-62. PubMed ID: 2861276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.